Occam Places Radu Dobrin as CTO of Deep Genomics
In June 2024, Occam performed a comprehensive biotech executive search and placed Radu Dobrin as the Chief Technology Officer of Deep Genomics, a Toronto-based artificial intelligence drug development venture. Dr. Dobrin brings diverse and extensive experience in various scientific and biopharmaceutical organizations at the intersection of computation and wet science.
He began his impressive career in drug research at Rosetta Inpharmatics, Merck, Johnson and Johnson Innovative Medicine, and Bristol Meyers Squibb (BMS) where he held the title Executive Director and Head of Bioinformatics Immunology & Oncology in TRCs and Early Development. He then shifted into biotechnology at Pathos, a clinical-stage biotech leveraging artificial intelligence (AI) for drug development, where he served as Senior Vice President (SVP) Translational Sciences.
In this new role, Dr. Dobrin will lead the further development of Deep Genomics proprietary AI foundation platform.
Dr. Dobrin holds a BS and MS in Physics from Babes-Bolyai University and an MS in Computer Engineering and PhD in Physics from Michigan State University.
About Deep Genomics
Founded in 2015 by Brendan Frey and funded by investors including SoftBank, and Khosla Ventures, Deep Genomics applies AI and machine-learning techniques to query RNA biology, discovering targets for its medicines and designing therapies that can address those targets. The Board is a formidable amalgamation of both tech and biotech luminaries, including Yann LeCun, Chief AI Officer of Meta.
About Deep Genomics Flagship AI Platform
Deep Genomics' proprietary AI platforms, including BigRNA, utilize comprehensive datasets, advanced machine learning systems, and rigorous protocols to revolutionize RNA therapeutics. BigRNA, the first RNA foundation model, excels in various tasks such as target identification, discovering novel biological mechanisms, predicting molecule-target interactions, and designing therapeutic candidates. Unlike traditional AI models focused on specific tasks, BigRNA's broad capabilities stem from its training on fundamental aspects of biology and chemistry, enabling it to predict RNA expression at sub-gene resolution and perform across different species and RNA therapeutic modalities. This positions BigRNA ahead of existing tools like Enformer, Saluki, and SpliceAI in a wide range of applications.
Occam Global’s Focus on Biotech Executive Search and Recruiting for Artificial Intelligence
Occam's vast experience in biotech executive search and recruiting for artificial intelligence and machine learning talent for life sciences organizations provides them with the network and skills to solve the most challenging searches. Several of Occam's clients incorporate AI/ML at one or multiple stages of R&D, and Occam has completed several searches across roles such as Chief Data Officer, Chief Technology Officer, and Chief Platform Officer.
Contact Occam Global for your biotech executive search and recruiting needs today.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.